The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines for ...

Highlights Walking pneumonia is a milder form of regular pneumonia. It can be contagious when caused by specific bacteria or ...

A single dose of the adult RSV vaccine RSVPreF3 OA prevented RSV–lower respiratory tract disease during 3 virus seasons in adults aged 60+.

Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction ...

Vermont has the second lowest state fatality rate in the US (147.3 per 100K; Hawaii 112.9/100K). Mississippi (464.7/100K) and ...

The nation’s infant mortality rate dropped last year after two years of hovering at a late-pandemic plateau. Some ...

As winter nears and the cold and flu season sets in, the highly infectious respiratory virus RSV has again begun its ...

Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.

Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings.

Former White House executive chef Cristeta Comerford says it was a “big eye-opener” to see that presidents and their families ...

Recent findings of the impact of new RSV prevention products aimed at protecting babies were published in the Morbidity and Mortality Weekly Report, an epidemiological digest prepared by the Centers ...

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.